Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
---|---|---|---|---|---|---|---|---|---|---|
|
0.710 | GeneticVariation | BEFREE | FGFR2 exons 7 and 12 unlabeled DNA probes allow for easy screening of endometrial carcinoma for the 2 most common FGFR2 mutations (S252W and N550K). | 21285871 | 2011 |
||||
|
C | 0.710 | CausalMutation | CLINVAR | ||||||
|
C | 0.700 | CausalMutation | CLINVAR | ||||||
|
0.020 | GeneticVariation | BEFREE | We cultured BaF3 cells overexpressing FGFR2 in high concentrations of dovitinib and identified 14 dovitinib-resistant mutations, including the N550K mutation observed in 25% of FGFR2(mutant) endometrial cancers (ECs). | 23908597 | 2013 |
||||
|
0.020 | GeneticVariation | BEFREE | We cultured BaF3 cells overexpressing FGFR2 in high concentrations of dovitinib and identified 14 dovitinib-resistant mutations, including the N550K mutation observed in 25% of FGFR2(mutant) endometrial cancers (ECs). | 23908597 | 2013 |
||||
|
0.020 | GeneticVariation | BEFREE | FGFR2 exons 7 and 12 unlabeled DNA probes allow for easy screening of endometrial carcinoma for the 2 most common FGFR2 mutations (S252W and N550K). | 21285871 | 2011 |
||||
|
0.020 | GeneticVariation | BEFREE | FGFR2 exons 7 and 12 unlabeled DNA probes allow for easy screening of endometrial carcinoma for the 2 most common FGFR2 mutations (S252W and N550K). | 21285871 | 2011 |
||||
|
0.010 | GeneticVariation | BEFREE | The mutation c.879C>T (p.Q289P) was first reported in endometrial cancer. | 25517871 | 2015 |
||||
|
0.010 | GeneticVariation | BEFREE | The mutation c.879C>T (p.Q289P) was first reported in endometrial cancer. | 25517871 | 2015 |
||||
|
0.010 | GeneticVariation | BEFREE | The mutation c.879C>T (p.Q289P) was first reported in endometrial cancer. | 25517871 | 2015 |
||||
|
0.010 | GeneticVariation | BEFREE | We also observed a nonsignificant inverse association with rs889312 (MAP3K1) variant carriers [OR = 0.85 (95% CI: 0.68-1.05)] and rs1219648 (FGFR2) variant carriers [OR= 0.86 (95% CI: 0.69-1.06) and endometrial cancer risk. | 18785201 | 2008 |